Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Poor Responders in IVF

In brief

Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients. Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum. The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.

Key facts

Study ID

NCT03560583

Run by

Barzilai Medical Center

People needed

60

Starts

2021-05-05

Expected to finish

2028-07-01

Last updated by the study team

2025-02-10

Who can join

Age: 18 and older, up to 54. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Poor response according to "Bologna criteria"

You may not qualify if…

• Allergy to metoclopramide
• Prolactinemia
• Women treated with dopamine agonists

Where it is running

• Barzilai University Medical Center — Ashkelon, Ashkelon District, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.